NasdaqGM:AXSMPharmaceuticals
Axsome Therapeutics (AXSM) Is Up 5.7% After AUVELITY Alzheimer’s Agitation Approval And Launch Push - Has The Bull Case Changed?
Axsome Therapeutics recently reported first-quarter 2026 results, with revenue of US$191.2 million and a net loss of US$64.54 million, and earlier in April received U.S. FDA approval for AUVELITY to treat agitation associated with dementia due to Alzheimer’s disease, backed by Phase 3 ADVANCE-1 and ACCORD-2 data.
The AUVELITY label expansion creates a new opportunity in Alzheimer’s-related agitation, a highly prevalent, costly, and difficult-to-manage symptom, while Axsome prepares a June...